MedTrace Logo

Dose-Escalating Multiple Dose Study of PD-0360324 in Combination With Methotrexate in Patients With Rheumatoid Arthritis

NCT00550355 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 78

Last updated 2009-07-14

No results posted yet for this study

Summary

This study is designed to evaluate the safety and tolerability of multiple intravenously administered doses of PD 0360324 in patients with rheumatoid arthritis receiving methotrexate.

Conditions

  • Arthritis, Rheumatoid

Interventions

DRUG

PD 0360324

3 doses of PD 0360324 (Dose level 1) administered over 12 weeks

DRUG

PD 0360324

3 doses of PD 0360324 (Dose level 2) administered over 12 weeks

DRUG

PD 0360324

3 doses of PD 0360324 (Dose level 3) administered over 12 weeks

DRUG

Placebo

3 doses of Placebo administered over 12 weeks

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
21 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-08-31
Primary Completion
2009-06-30
Completion
2009-06-30

Countries

  • United States
  • Argentina
  • Bulgaria
  • Czechia
  • Mexico
  • Poland
  • Slovakia
  • Spain

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00550355 on ClinicalTrials.gov